EGFR/ ALK-negative Advanced NSCLC
1 clinical trials · Condition
◉ Watch EGFR/ ALK-negative Advanced NSCLC
| Record | Firm | Date |
|---|---|---|
| Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC (NCT06260553) | Fujian Cancer Hospital | 2024-02-07 |
Track EGFR/ ALK-negative Advanced NSCLC automatically
Every clearance here is in the API, with alerts when new ones post.